Which patients with high-risk NMIBC are you selecting for durvalumab plus BCG (POTOMAC) over BCG monotherapy alone?
Does the current non-significant OS data mean we should really be prioritizing patients with highest-risk disease? How will you define that?
Community PollStarted
For which patients are you planning to add durvalumab to BCG (POTOMAC regimen) for high risk NMIBC?
3 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet Member
Urology · Penn State Health
Answered on
I'm not selecting patients for these therapies right now. POTOMAC is clearly a positive trial, with a 32% reduction in the risk of recurrence or progression with durvalumab plus BCG induction and maintenance, and the benefit was sustained with more than five years of follow-up. However, what also st...
Join for free or sign in to see the full answer
Mednet Member
Medical Oncology · University of California Los Angeles, Los Angeles
Answered on
The vast majority of patients with bladder cancer have NMIBC, and first-line BCG has been the standard of care for several decades now. The high-risk patients for POTOMAC are those who have high-grade Ta, T1, and carcinoma in situ, those with recurrent papillary tumors, >3 cm lesions, multiple tumor...
Join for free or sign in to see the full answer